Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 1;12(2):111-116.

A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer

Nuri Karadurmus  1 , Ugur Sahin  2 , Bilgin Bahadir Basgoz  1 , Fikret Arpaci  3 , Taner Demirer  2
Affiliations
Review

A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer

Nuri Karadurmus et al. Int J Hematol Oncol Stem Cell Res. .

Abstract

Breast cancer (BC) has a high mortality rate and metastatic BC is almost incurable despite hormonal therapy and chemotherapy. The second and third lines of chemotherapies usually yield transient responses and the median survival is generally as low as 18-24 months. Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) have been extensively investigated in this setting. The presence of immune mediated anti-tumor effects referred to as graft-versus-tumor (GvT) effects after allogeneic HSCT among patients with solid tumors have been clearly defined. The advantages of allogeneic HSCT over autologous HSCT for metastatic BC are i) cancer-free graft and ii) immune-mediated GvT effects mediated by human leukocyte antigen compatible donor T-cells. In conclusion, a GvT effect does exist against metastatic BC and play a key role in tumor response. This review aims to describe the background, rationale, and clinical results of allogeneic HSCT as a potential alternative treatment in metastatic BC.

Keywords: Allogeneic hematopoietic stem cell transplantation; Metastatic breast cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339(14):974–84. - PubMed
    1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92. - PubMed
    1. Crown J, DiérasV , Kaufmann M, et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol. 2002;3(12):719–27. - PubMed
    1. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2(11):1281–8. - PubMed

LinkOut - more resources